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Abstract
Background: The metabolic syndrome, known also as the insulin resistance syndrome, refers to the clustering of
several risk factors for atherosclerotic cardiovascular disease. Dyslipidaemia is a hallmark of the syndrome and is
associated with a whole body reduction in the activity of lipoprotein lipase (LPL), an enzyme under the regulation
of the class of nuclear receptors known as peroxisome proliferator-activated receptor (PPAR). Glycyrrhizic acid (GA),
a triterpenoid saponin, is the primary bioactive constituent of the roots of the shrub Glycyrrhiza glabra. Studies
have indicated that triterpenoids could act as PPAR agonists and GA is therefore postulated to restore LPL
expression in the insulin resistant state.
Results: Oral administration of 100 mg/kg of GA to high-fat diet-induced obese rats for 28 days led to significant
reduction in blood glucose concentration and improvement in insulin sensitivity as indicated by the homeostasis
model assessment of insulin resistance (HOMA-IR) (p < 0.05). LPL expression was up-regulated in the kidney, heart,
quadriceps femoris, abdominal muscle and the visceral and subcutaneous adipose tissues but down-regulated in
the liver - a condition in reverse to that seen in high-fat diet-induced obese rats without GA. With regard to lipid
metabolism, GA administration led to significant hypotriglyceridemic and HDL-raising effects (p < 0.05), with a
consistent reduction in serum free fatty acid, total cholesterol and LDL cholesterol and significant decrease in tissue
lipid deposition across all studied tissue (p < 0.01).
Conclusion: In conclusion, GA may be a potential compound in improving dyslipidaemia by selectively inducing
LPL expression in non-hepatic tissues. Such up-regulation was accompanied by a GA-mediated improvement in
insulin sensitivity, which may be associated with a decrease in tissue lipid deposition. The HDL-raising effect of GA
suggests the antiatherosclerotic properties of GA.
Background
The metabolic syndrome (MetS), known also as the
insulin resistance syndrome and syndrome X, refers to
the clustering of several risk factors for atherosclerotic
cardiovascular disease. Insulin resistance (IR) is recog-
nized as the potential underlying etiology of the various
metabolic abnormalities that comprises the syndrome,
of which includes abdominal obesity, glucose intoler-
ance, atherogenic dyslipidaemia and hypertension. Indi-
viduals with the syndrome are at a 2- and 5-fold
increased risk for the development of cardiovascular dis-
eases and diabetes mellitus respectively [1-3].
Various studies have shown that with the development
of IR, the production and activity of the enzyme lipopro-
tein lipase (LPL) is reduced [4,5]. LPL acts to hydrolyze
the core triacylglycerol (TAG) of circulating TAG-rich
lipoproteins to regulate the entry of fatty acids into the
underlying tissues [5,6]. Reduced LPL activity has been
s h o w nt ol e a dt oa ni n h i b i t i o ni nt h el i p o l y t i cr a t eo ft h e
chylomicrons and the very-low-density lipoproteins
(VLDL), triggering the development of hypertriglyceri-
daemia and the subsequent dyslipidaemia seen in the
MetS [7,8].
Stimulation of LPL activity by either the use of trans-
genic overexpression or the administration of LPL-
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dyslipidaemia. Systemic overexpression of the human
LPL transgene in Watanabe heritable hyperlipidemic
(WHHL) rabbits which mimic the features of MetS in
humans, for example, led to a significant decrease in
plasma TAG levels and corrected the hypercholesterole-
mia in these animal models [9]. In addition, targeted
over-expression of LPL in skeletal muscle of transgenic
mice lowered both plasma TAG and FFA levels even
upon high-fat feeding [10].
Currently available classes of LPL-raising drugs include
the fibrates, thiazolidinediones (TZDs) and the NO-1886
(ibrolipim). Both the fibrates and TZD are peroxisome
proliferator-activated receptor (PPAR) agonists that act on
the isoforms PPAR-a [7] and PPAR-g [11] respectively to
induce an increase in LPL activity. These PPAR nuclear
receptors then bind to the peroxisome proliferator
response element (PPRE) present in the promoter region
of the LPL gene [12]. Despite the effectiveness of fibrates
however, patients on long-term fibrate therapy suffer from
an increased incidence of cholesterol gallstone [13]. The
TZDs on the other hand is associated with fluid retention
and plasma volume expansion which lead to peripheral
edema. This increases the incidence of heart failure in
some patients, with a frequency of 2.5 times greater in
patients on combination therapy with insulin [14]. Lastly,
NO-1886 has been reported to inhibit basal and adreno-
corticotrophic hormone (ACTH)-induced release of ster-
o i dh o r m o n e si nr a t ,d o g ,m o n k e ya n dh u m a n
adrenocortical cells, resulting in hypertrophy of the adre-
nals [15]. With such drawbacks, the development of an
alternative LPL-promoting agent is therefore needed.
Glycyrrhizic acid (GA), a triterpenoid saponin, is the
primary bioactive constitue n to ft h er o o t so ft h es h r u b
Glycyrrhiza glabra. Interest in GA arose following dis-
coveries that excess tissue glucocorticoid action, ampli-
fied by the enzyme 11b-hydroxysteroid dehydrogenase
type 1 (11b-HSD1), could promote the symptoms of the
MetS. GA and its active metabolite glycyrrhetic acid act
as potent inhibitors of 11b-HSD1 [16]. More impor-
tantly however, is that triterpenoids had been discovered
to act as PPAR agonists [17,18] and this may suggest
that GA could also potentially act to activate the PPAR
class of nuclear receptors and may therefore be pro-
posed to be a candidate for raising LPL. In this study,
the expression of LPL, insulin sensitivity and lipid para-
meters are compared between high-fat diet-induced
obese rats treated and non-treated with GA.
Results
GA treatment restored LPL expression in obese-induced
rats
In comparing between rats on normal diet (group A)
and rats on high-fat diet (group B), LPL expression was
downregulated in all tissues in the latter except the liver
(Figure 1). The heart showed the highest decrease with
a fold difference of -4.184 ± 0.25, followed by the
abdominal muscle (AM) (- 4.059 ± 0.31), kidney
(-2.483 ± 0.32 fold), subcutaneous adipose tissue (SAT)
(-2.924 ± 0.39 fold), quadriceps femoris (QF) (-1.970 ±
0.65) and visceral adipose tissue (VAT) (-1.361 ± 0.76).
No significant differences were seen in any of the tissues
when comparing the two groups (p > 0.05). In the liver,
LPL was up-regulated by 1.539 ± 1.10 fold (p > 0.05).
When comparing rats from group B with group C (rats
on high-fat diet and given 100 mg/kg of GA), the
reverse was observed where LPL expression was up-
regulated in all tissues in the latter group (Figure 2)
except the liver. The highest up-regulation was observed
in the QF (fold difference = 2.786 ± 2.22) followed by
the AM (2.715 ± 2.65), heart (2.076 ± 1.78), SAT
(1.935 ± 1.89), kidney (1.486 ± 1.38) and VAT (1.058 ±
0.35). These increases were not significant (p > 0.05).
LPL expression in the liver was down-regulated by a fold
of -1.443 ± 0.71 and this was not significant (p > 0.05).
GA treatment improved insulin sensitivity in obese-
induced rats
Mean blood glucose concentrations of rats from groups
A, B and C were 5.63 ± 0.92 mmol/L, 7.60 ± 1.35
mmol/L and 4.57 ± 0.30 mmol/L respectively (Figure 3).
Rats from group C presented a significant decrease com-
pared to group B (p < 0.05) but non-significant decrease
compared to group A (p > 0.05). Mean serum insulin
concentrations of rats from groups A, B and C were
Figure 1 Relative LPL expression of Group B compared to A.
Fold difference of LPL expression in tissues studied, using b-actin
(BAC) as the endogenous reference, tissues of rats from group A as
the calibrator and tissues of rats from group B as the target. LPL
expression was down-regulated in all tissues except the liver. [Group
A: rats fed on normal diet without GA; Group B: rats fed on high-fat
diet without GA].
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ng/mL respectively (Figure 4). This represented a signifi-
cant increase when comparing between group A with
groups B (p < 0.05) and C (p < 0.05). However no sig-
nificant difference was seen between groups B and C
(p > 0.05). Analysis of the HOMA-IR showed that rats
from group B (0.23 ± 0.03) had the highest HOMA-IR
index compared to groups A (0.11 ± 0.02) and C (0.12
± 0.02) with a significant increase in groups B relative
to A (p < 0.01) but a non-significant increase in groups
C relative to A (p > 0.05). The HOMA-IR index
decrease in group C was significant compared to group
B (p < 0.05) (Figure 5).
GA treatment led to a positive shift in serum lipid in
obese-induced rats
Overall, rats from group C had improved lipid profile
with a 6.80% decrease in total cholesterol, 22.33%
Figure 2 Relative LPL expression of Group C compared to B.
Fold difference of LPL expression in tissues studied, using BAC as
the endogenous reference, tissues of rats from group B as the
calibrator and tissues of rats from group C as the target. LPL
expression was up-regulated in all tissues except the liver. [Group B:
rats fed on high-fat diet without GA; Group C: rats fed on high-fat
diet and given 100 mg/kg of GA].
Figure 3 Comparison of blood glucose. Mean concentration of
blood glucose (mmol/L) of rats from groups A, B and C. * indicates
p < 0.05 when compared between groups. [Group A: rats fed on
normal diet without GA; Group B: rats fed on high-fat diet without
GA; Group C: rats fed on high-fat diet and given 100 mg/kg of GA].
Figure 4 Comparison of serum insulin. Mean concentration of
serum insulin (ng/mL) of rats from groups A, B and C. * indicates p
< 0.05 when compared between groups. [Group A: rats fed on
normal diet without GA; Group B: rats fed on high-fat diet without
GA; Group C: rats fed on high-fat diet and given 100 mg/kg of GA].
Figure 5 Comparison of HOMA-IR. Mean HOMA-IR of rats from
groups A, B and C. ** indicates p < 0.01 and * indicates p < 0.05
when compared between groups. [Group A: rats fed on normal diet
without GA; Group B: rats fed on high-fat diet without GA; Group C:
rats fed on high-fat diet and given 100 mg/kg of GA].
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increase in HDL and 7.32% decrease in serum FFA
(Figure 6). Comparison of lipid profiles of rats from
groups A, B and C showed that mean total cholesterol
was the highest in rats from group B (2.94 ± 0.94
mmol/L) compared to groups A (2.60 ± 0.32 mmol/L)
and C (2.74 ± 0.14 mmol/L). No significant difference
was observed between all groups. TAG concentrations
in groups A, B and C were 0.58 ± 0.02, 1.03 ± 0.07 and
0.80 ± 0.07 mmol/L respectively. A significant increase
(77.59%) was observed in group B compared to A (p <
0.01) while a significant decrease (22.33%) was seen in
group C compared to B (p < 0.05). HDL concentrations
in groups A, B and C were 1.86 ± 0.16, 1.72 ± 0.05 and
1.93 ± 0.06 mmol/L respectively and this represented a
significant increase (12.21%) in group C compared to B
(p < 0.05). LDL concentrations showed no significant
difference between all three groups which has a level of
0.55 ± 0.15 (group A), 0.75 ± 0.11 (group B) and 0.65 ±
0.12 (group C) mmol/L respectively. Lastly, FFA levels
were 1.05 ± 0.04, 1.23 ± 0.16 and 1.14 ± 0.14 mmol/L
respectively for groups A, B and C with no significant
difference between any groups.
GA treatment reduced tissue lipid deposition in obese-
induced rats
Tissue lipid deposition was significantly increased in all
tissues of groups B and C compared to A, and was sig-
nificantly reduced in all tissues of group C compared to
B (p < 0.01 in all cases) (Figure 7). Mean lipid deposi-
tion in all the five lobes of the liver from groups A, B
and C were 8.88 × 10
2 ± 5.45 AU, 1.46 × 10
3 ± 9.06 AU
and 1.07 × 10
3 ± 3.64 AU respectively. This represented
an increase of 39.18% and 17.00% respectively when
comparing groups B and C with A and a decrease of
26.71% in group C compared to B. Mean lipid deposi-
tion in both kidneys from groups A, B and C were
3.75 × 10
2 ± 10.39 AU, 1.41 × 10
3 ± 10.04 AU and 8.85
×1 0
2 ± 4.12 AU respectively, indicating a 67.11% and
57.63% increase in groups B and C relative to A and a
22.37% decrease in group C relative to B. For the three
muscle groups studied, QF lipid deposition showed a
52.70% and 48.68% increase in groups B and C relative
to A and 7.83% decrease in group C relative to B (group
A, 44 × 10
2 ±5 . 0 2A U ;B ,1 . 1 5×1 0
3 ±3 . 7 4A U ;C ,
1.06 × 10
3 ± 3.00 AU), AM lipid deposition charted a
50.36% and 47.05% increase in groups B and C relative
to A and an accompanying 6.25% decrease in group C
relative to B (group A, 5.56 × 10
2 ±7 . 5 3A U ;B , 1 . 1 2×
10
3 ± 1.44 AU; C, 1.05 × 10
3 ± 5.47 AU) and heart lipid
deposition showed an increase of 59.77% and 48.1% in
groups B and C relative to A and a decrease of 22.48%
in group C relative to B.
Discussion
Numerous studies have revealed that high-fat diets pro-
mote hyperglycemia and whole-body IR. It is generally
accepted that high-fat diets can be used to generate a
valid rodent model for the MetS with IR [19]. Overfeed-
ing of animals with high-fat diet of more than 50% of
calories as fat for approximately five weeks is sufficient
Figure 6 Comparison of serum lipid. Mean concentration of total
cholesterol, TAG, HDL-cholesterol, LDL-cholesterol and serum FFA in
rats from groups A, B and C. ** indicates p < 0.01 and * indicates p
< 0.05 when compared between groups. [Group A: rats fed on
normal diet without GA; Group B: rats fed on high-fat diet without
GA; Group C: rats fed on high-fat diet and given 100 mg/kg of GA].
Figure 7 Comparison of tissue lipid deposition. Lipid deposition
in tissues studied, measured in arbitrary units (AU). Sections of VAT
and SAT were used as positive controls. ** indicates significant
increase in lipid deposition when comparing between Group A with
each of Groups B and C, and a significant decrease in lipid
deposition in Group C compared to B (p < 0.01). [Group A: rats fed
on normal diet without GA; Group B: rats fed on high-fat diet
without GA; Group C: rats fed on high-fat diet and given 100 mg/kg
of GA].
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[20,21]. In the present study, rats were fed a high-fat
diet with 60% of calories from vegetable shortening for
four weeks. Rats fed a high-fat diet consumed signifi-
cantly more calories on a per day basis compared to the
controls which were only fed standard rat chow.
In the insulin resistant state, the decrease in insulin-
mediated suppression of lipolysis in adipocytes promotes
the release of fatty acids which inhibits LPL activity [22].
When supply of fatty acids exceeds tissue demand, fatty
a c i d sw o u l dp r o b a b l yb i n dt oL P La n dd i s p l a c ei tf r o m
its binding sites, thereby rendering them non-functional
[23]. LPL expression of rats fed on high-fat diet without
GA (group B) was down-regulated in all non-hepatic tis-
sues compared to the controls (group A). The down-
regulation of LPL in the adipose tissues, muscles and
kidney under study may be due to inflammatory media-
tors such as tumour necrosis factor-alpha (TNF-a)
w h i c ha r ef o u n dt ob ee l e v a t e di no b e s i t ya n di n s u l i n
resistant states [24]. Its inhibition of LPL gene transcrip-
tion is suggested to be mediated in part by blocking the
nuclear-factor-Y/CCAAT interactions with LPL promo-
ter [6,25]. However, the increase in TNF-a level renders
an opposing effect in the liver. According to Wang and
Eckel [26], LPL is not normally expressed in the adult
liver of animals but can be expressed under specific
physiological and pathological conditions. A single dose
of TNF-a can cause a significant increase in LPL
mRNA levels in the liver. However, the detailed
mechanism of such induction is not well understood.
The increase in hepatic LPL activity and its concomitant
decrease in the non-hepatic tissues could have resulted
in greater partitioning of plasma TAG to the liver and
increased hepatic uptake of FFAs. This would lead to an
increase in the secretion of VLDL-TAG and apolipopro-
tein B100 (apoB100) from the liver [27], and hence may
account for the observed hypertriglyceridaemia in group
B compared to group A.
In rats on high-fat diet given GA (group C), LPL
expression was up-regulated in all non-hepatic tissues, a
condition that opposes that seen in group B. It was pos-
tulated that GA results in the up-regulation of LPL
expression via the activation of PPAR class nuclear
receptors since the LPL gene was found downstream of
the transcriptionally active PPRE [5]. Of the tissues in
which LPL expression was up-regulated, the highest up-
regulation took place mainly in the muscles (AM, QF
and heart) compared to the SAT and VAT (Figure 2).
T h i ss u g g e s tt h a tG Am a ye x h i b i tah i g h e rp o t e n c yi n
activating PPARa than PPARg;P P A R a is highly
expressed in the heart, muscles, liver and kidney in
which it has a crucial role in controlling fatty acid oxi-
dation [28], while PPARg is highly expressed in the adi-
pocytes where it triggers adipocyte differentiation and
lipogenesis [6]. The activation of PPARa may lead to a
direct up-regulation of LPL expression and also down-
regulate apo- CIII, an inhibitor of LPL [29] that is
up-regulated in the insulin resistant state [8]. The down-
regulation of LPL expression in the liver might be due
to the reduction in macrophage-derived TNF-a in the
adipose tissue. According to Jeong and Yoon [30],
PPARa activation in adipose tissue decrease mRNA
levels of TNF-a which eventually inhibit adipocyte
hypertrophy in obese animals. Hence, GA is postulated
to activate PPARa in the adipose tissues to decreases
TNF-a production and subsequently down-regulate LPL
in the liver. The end effect of these is that GA thus pro-
motes partitioning of lipids away from the liver into the
oxidative tissues.
Improvement in lipid profile following GA treatment
in obese-induced rat was similar to that previously
reported by Lim et al. [31] in lean rats, but with a more
prominent hypotriglyceridemic and HDL-raising effect.
The hypertriglyceridaemia observed in patients with the
MetS and T2DM originates from (i) lipolysis of TAG
store from adipose tissue that causes elevated FFA flux
to the liver and hence, increased hepatic TAG synthesis
and (ii) inhibition of lipolysis of chylomicrons and
VLDL due to decreased LPL levels [8]. Our present
study indicated that GA administration in obese rats
could curb such development by its selective induction
of LPL expression in the non-hepatic tissues to promote
catabolism of circulating TAG-rich lipoproteins and pre-
vent further uptake of FFA into the liver by down-regu-
lating hepatic LPL expression. More importantly, GA
induced a significant increase in HDL levels in the
obese rats. Elevating HDL-cholesterol may serve as a
more attractive treatment alternative instead of lowering
LDL cholesterol as dyslipidaemia is often characterized
by a normal range of serum LDL-cholesterol, but with a
predominance of the more atherogenic small, dense
LDL rather than the less atherogenic large, buoyant
LDL particles [7]. The atheroprotective effect of HDL is
exerted through its ability to counteract LDL oxidation,
the major initiating event that prompts the development
of atherosclerosis. The HDL particle, by virtue of the
antioxidative properties of its attached apo A-I, paraoxo-
nase and glutathione peroxidase, reduces the oxidative
modification of LDL by quenching the oxygen-derived
free radicals generated from LDL oxidation [32]. Hence,
various pharmacological interventions have been focused
on raising HDL-cholesterol levels [32].
Obesity induced-IR results in profound dysregulation
in the glucose homeostasis, and produces elevations in
fasting and postprandial glucose levels [33]. As seen in
the present study, the mean blood glucose concentration
was increased in group B compared to group A. With the
development of visceral obesity, the high circulating FFA
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glycaemia by (i) down-regulating the insulin-sensitive
g l u c o s et r a n s p o r t e r4( G L U T 4 )v i at h eR a n d l ec y c l ea n d
hence promotes an accumulation of glucose in the circu-
lation and (ii) stimulating hepatic gluconeogenesis by
antagonizing the action of insulin in the liver (hepatic IR)
[8]. GA-treated rats in group C demonstrated a signifi-
cant decrease in fasting blood glucose compared to
group B. The reduction in fasting blood glucose of the
GA-treated group is proposed to be accounted for by
increased tissue glucose uptake via GLUT4. PPAR-g acti-
vation in the adipose tissue has been shown to increase
the expression of the c-Cbl associating protein (CAP)
that is important for the translocation of GLUT4 to the
cell surface [33] and inhibition of 11b-HSD1 may also
exhibit similar effect by attenuating the inhibition of
muscle GLUT4 translocation by active glucocorticoids
[34]. These effects may therefore increase glucose dispo-
sal, giving a decrease in circulating glucose levels. More
importantly, both 11b-HSD1 inhibition and PPAR-g
agonism have also been associated with reduced expres-
sion of phosphoenolpyruvate carboxykinase (PEPCK) and
glucose-6-phosphatase (G6Pase) [35,36], the two rate-
limiting enzymes of the gluconeogenesis pathway that is
aberrantly induced in T2DM patients [34]. Uncontrolled,
accelerated gluconeogenesis accounts for 90% of hepatic
glucose output in T2DM patients and is thereby a signifi-
cant contributor to hyperglycaemia [35].
Besides a significant reduction in blood glucose con-
centration in group C, mean serum insulin concentra-
tion was also reduced as compared to group B. This
might be due to improved glucose-sensing proteins in
the pancreatic b-cells since b-cells controls insulin
secretion in response to blood glucose concentration
[37]. Briefly, both the GLUT2 transporter and the
enzyme glucokinase (GK) are components of the glu-
cose-sensing apparatus of the b-cells whose expression
are both decreased in diabetes. With this, the glucose
threshold for insulin secretion is also decreased, leading
to aberrant insulin secretion and hyperinsulinaemia.
PPAR-g activation is shown to restore both GLUT2 and
GK expression [36]. Hence the glucose threshold for
insulin secretion is increased, reducing insulin secretion.
The HOMA-IR is used for the assessment of insulin
sensitivity from basal (fasting) glucose and insulin levels;
a higher value indicating lower insulin sensitivity (higher
insulin resistance) and vice versa [38]. The HOMA-IR
index decrease in group C was significant compared to
group B - indicating an improvement in insulin sensitiv-
ity in rats on high-fat diet and given 100 mg/kg of GA.
Chronic obesity has been associated with non-adipose
tissue lipid accumulation - a condition known as tissue
steatosis [8,39]. During conditions of chronic caloric
excess, a compensatory mechanism first occur in the
leptin-responsive state whereby the surplus FFA up-regu-
lates PPARa and promote the compensatory oxidation of
the surplus FFA, with the excess energy dissipated as heat.
As such process continues, such caloric excess is no longer
compensated and in the leptin-unresponsive state, the sur-
plus FFA activates PPARg instead, leading to up-regulation
of the lipogenic enzymes that cause ectopic TAG accumu-
lation [39]. Leptin resistance has been reported to occur in
late phases in both rat and human diet-induced obesity
[39]. Our present study has shown that lipid depositions
in all the tissues of group C rats were significantly reduced
compared to group B. We postulate that such observation
is accounted for by GA activation of PPARa that induces
the expression of lipid-catabolizing genes such as carnitine
palmitoyltransferase-1 (CPT-1), acyl CoA oxidase (ACO)
a n du n c o u p l i n gp r o t e i n( U C P - 2 )t h a ta r ei n d u c e dn o r -
mally in the state of compensated caloric excess aforemen-
tioned. Tissue lipid accumulation has been associated
with obesity-related IR [40,41] and these are mediated by
TAG-derived metabolites that inhibits insulin signal trans-
duction [42]. Thus, our observation of GA-mediated
improvement in insulin sensitivity may be related to such
decrease in tissue lipid as well.
Conclusion
Our study has indicated that daily oral administration of
100 mg/kg of GA to high-fat dietinduced obese rats for
28 days led to significant improvement in insulin sensi-
tivity, together with an apparent hypotriglyceridaemic
and HDL-raising effect. LPL expression was upregulated
mainly in the oxidative tissues and this may promote
catabolism of the TAG-rich VLDL and chylomicron that
usually accumulate in the circulation of MetS patients.
Lastly, a decrease in tissue lipid deposition was observed
with GA administration - possibly associated with an
increase in fatty acid oxidation.
Methods
Animal treatment
The use and handling procedure of animals in this
research project had been approved by the Monash Uni-
versity Animal Ethics Committee (AEC Approval Num-
ber: SOBSB/MY/2007/22). 24 male Sprague-Drawley
rats (Rattus norvegicus) with an initial weight between
160 g to 200 g were randomly chosen and were housed
individually in plastic cages with a 12:12-h light-dark
cycle - lights starting at 0600 hours. The room was kept
at 23.0°C ± 1.0°C. Before the experiment, rats in all
groups were fed ad libitum with free access to standard
rat chow (Gold Coin, Malaysia) and tap water. At the
start of this experiment, each of the 3 groups were sub-
jected to different dietary composition and treatment -
Group A was fed on a normal diet; Group B was fed on
high-fat diet; Group C was fed on high-fat diet and
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high-fat diet pellets were prepared by mixing powdered
rat chow to vegetable shortening in a ratio of 2:3. All
three groups of rats were fed and treated for 28 days.
The amount of food and water or GA consumed was
recorded daily.
Sample collection
Rats in all groups were fasted for approximately
12 hours prior to sacrifice. The rats were anaesthetized
by intraperitoneal injection of 150 mg/kg of sodium
pentobarbital (Nembutal) and dissection was carried out
between 0800 and 1000 hours. Blood was drawn from
the apex of the cardiac ventricle and five drops of blood
were collected into a microcentrifuge tube containing a
mixture of EDTA and NaF in a 1:2 (w/w) ratio. This ali-
quot of blood will be used for blood glucose determina-
tion. The remaining blood sample was collected into a
sterile Falcon tube and centrifuged at 12,000 × g for
10 minutes. The serum supernatant was aliquoted into
microcentrifuge tubes and stored at -80°C until required
for analysis. The seven tissues of interest, namely, the
heart, kidney, liver, AM, QF, VAT and SAT were
promptly harvested and immediately flash-frozen in
liquid nitrogen and stored at -80°C.
Blood biochemistry analysis
Blood glucose was determined using the Trinder’sg l u -
cose oxidase method while serum insulin was deter-
mined using the Rat/Mouse Insulin ELISA Kit (Linco
Research, USA). The HOMA-IR was calculated as the
product of fasting blood glucose and serum insulin
divided by 22.5 [38]. Serum FFA, TAG and total choles-
terol were determined using the Zenbio 96- well Serum/
Plasma Fatty Acid Kit Non-Esterified Fatty Acids Detec-
tion 100 point kit (Zenbio, USA), Randox Triglycerides
Kit (Randox, UK) and Randox CH200 Cholesterol Kit
(Randox, UK) respectively. HDL-cholesterol was deter-
mined using the aforementioned cholesterol kit after
precipitation of HDL using the Randox CH203 HDL
Precipitant Kit (Randox, UK). LDL-cholesterol was cal-
culated using the levels of total cholesterol, TAG, HDL-
cholesterol obtained using the Friedewald formula [43].
Real time reverse transcription polymerase chain reaction
(qRT-PCR) of LPL gene
Qiagen RNeasy Mini kit (Qiagen, USA) was used to iso-
late the total RNA from the liver, kidney, AM and QF
while Qiagen RNeasy Lipid Tissue Mini kit was used to
isolate the total RNA from SAT and VAT (Qiagen,
USA). The purity of the RNA was determined by deter-
mining the absorbance values at 260 nm and 280 nm
(A260/A280 ratio) where a ratio of 1.9-2.1 is considered
pure. Promega RQ1 RNase-free DNase (Promega, USA)
was used for the RNase-free DNase treatment and lastly,
Qiagen Omniscript Reverse Transcriptase kit (Qiagen,
USA) was used for cDNA synthesis. Relative LPL
expression was determined by qT-PCR using the Com-
parative Ct (ΔΔCt) Method, normalized to the BAC
gene. Sequence of primers and probes specific to Rattus
norvegicus LPL [GenBank: BC081836] and BAC [Gen-
Bank: BC063166] mRNA are as follows:
LPL, forward: 5′-CAGCAAGGCATACAGGTG-3′
LPL, reverse: ‘-CGAGTCTTCAGGTACATCTTAC-3′
LPL, probe: 5′-(6-FAM) TTCTCTTGGCTCTGACC
(BHQ1)-3′
BAC, forward: 5′-GTATGGGTCAGAAGGACTCC-3′
BAC, reverse: 5′-GTTCAATGGGGTACTTCAGG-3′
BAC, probe: 5′-(TET) CCTCTCTTGCTCTGGGC
(BHQ1)-3′
Agarose gel electrophoresis was performed on ampli-
cons produced from qRT-PCR to assess primer
specificity.
Tissue lipid quantification
Frozen tissues were cut into cubes of 5 × 5 × 5 mm on
a sterile petri dish and fixed onto a cryotome at -25°C
using the Optimal Cutting Temperature (OCT) Com-
pound (Leica, Germany). Sections of 5 μmt h i c kw e r e
stained with ORO using the method of Koopman et al.
[44] and captured at 400× magnification. Lipid deposi-
tions for all tissues were calculated as per Goodpaster et
al. [40]. Briefly, captured images were converted to gray
scale on Image J software and the threshold for staining
intensity was adjusted to selectively pick up lipid dro-
plets. Pixels with intensities of 150 ± 30 arbitrary unit
(AU) were selected (intensity ranges from 0AU to
255AU; 0AU represented complete staining and 255AU
represented no staining). The mean of eight values from
eight contiguous views captured was used to determine
the level of lipid deposition in arbitrary units (AU).
Lipid deposition
Areastained(%) Meanstainintensity
106 =
Statistical analysis
Statistical analysis for LPL expression was performed
using the Relative Expression Software Tool (REST
©)
MCS Beta 2006. All other data were analyzed using Sta-
tistics Package for the Social Sciences (SPSS) for Win-
dows Version 16.0. Data distribution was analyzed using
the Kolmogorov-Smirnov normality test. Data with para-
metric distribution were then analyzed using Analysis of
Variance (ANOVA) and if the results were significant, a
Post Hoc Scheffe test was performed. Data with non-
parametric distribution was analyzed using Kruskall-
Wallis test. All data in this study were found to be
Eu et al. Lipids in Health and Disease 2010, 9:81
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Page 7 of 9parametric and hence were all reported as mean ± stan-
dard error. In all analyses, a p-value of ≤ 0.05 was con-
sidered statistically significant.
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